Archives

  • 2019-10
  • 2019-11
  • 2020-03
  • 2020-07
  • 2020-08
  • 2021-03
  • br ACCEPTED MANUSCRIPT br Generalizability br The results of

    2020-08-06


    ACCEPTED MANUSCRIPT
    4.4. Generalizability
    The results of this paper supported the results of previous studies as well as the rationale existing behind the tumor biology. All together show the external validity of our work. Although the significant association of KIR2DS5 did not remain significant after Bonferroni's correction, however this external validation suggest that this result cannot be due to alpha error.
    ACCEPTED MANUSCRIPT
    5. Other information
    This study is MSc thesis of Bahareh Shayanrad and supported by Lorestan University of Medical Sciences.
    5.2. Ethical Consideration
    This study is approved by the ethic committee of Lorestan University of Medical Sciences with ethic code IR.LUMS.REC.1396.247. The informed consent were taken from the participants and we observed their privacy and registry-based information.
    We declare that there is no personal or commercial conflict of interest. The named products are merely for their previous scientific validation and we do not have any commercial aim. The only personal interest of publishing this paper is reporting the thesis results and our legal obligation to our university. We previously published a meta-analysis on this title and we declare that there is no self-plagiarism or salami publishing; we were just intend to update that meta-analysis with the results of our ethnicity.
    ACCEPTED MANUSCRIPT
    References
    [2] Hammad Akhtar M, Masud K, Junaid Nazar CM, Mumtaz MY, Bhatti TK, Frequency of colorectal dysplasia and cancer among young patients with ulcerative colitis in a tertiary care hospital, Immunopathologia Persa 2017;3:e04-07.
    [6] Suman S, Sharma PK, Rai G, Mishra S, Arora D, Gupta P, et al., Current perspectives of molecular pathways involved in chronic Inflammation-mediated breast cancer, Biochemical and biophysical research communications 2016;472:401-409.
    [9] Little J, Higgins JP, Ioannidis JP, Moher D, Gagnon F, von Elm E, et al., STrengthening the REporting of Genetic Association Studies (STREGA)--an extension of the STROBE statement, Genetic epidemiology 2009;33:581-598.
    [10] Hollenbach JA, Mack SJ, Gourraud PA, Single RM, Maiers M, Middleton D, et al., A community standard for immunogenomic data reporting and analysis: proposal for a STrengthening the REporting of Immunogenomic Studies statement, Tissue Methoxy-X04 2011;78:333-344.
    [11] Akbari S, Ahmadi SAY, Shahsavar F, The relationship of maternal KIR and parental HLA -C genes with risk of recurrent spontaneous abortion: a regional study in Lorestan Province, Iran, Crescent Journal of Medical and Biological Sciences 2018;5:194-197.
    [12] Rodriguez S, Gaunt TR, Day IN, Hardy-Weinberg equilibrium testing of biological ascertainment for Mendelian randomization studies, American journal of epidemiology 2009;169:505-514.
    [13] Middleton D, Vilchez J, Cabrera T, Meenagh A, Williams F, Halfpenny I, et al., Analysis of KIR gene frequencies in HLA class I characterised bladder, colorectal and laryngeal tumours, HLA 2007;69:220-226.
    [14] Kim H-J, Choi H-B, Jang J-P, Baek I-C, Choi E-J, Park M, et al., HLA-Cw polypmorphism and killer cell immunoglobulin-like receptor (KIR) gene analysis in Korean colorectal cancer patients, International Journal of Surgery 2014;12:815-820.
    [15] Al Omar SY, Mansour L, Dar JA, Alwasel S, Alkhuriji A, Arafah M, et al., The relationship between killer cell immunoglobulin-like receptors and HLA-C polymorphisms in colorectal cancer in a Saudi population, Genetic testing and molecular biomarkers 2015;19:617-622.
    [16] Portela P, Merzoni J, Lindenau JD, Damin DC, Wilson TJ, Roesler R, et al., KIR genes and HLA class I ligands in a Caucasian Brazilian population with colorectal cancer, Human immunology 2017;78:263-268.
    [17] Robles AI, Traverso G, Zhang M, Roberts NJ, Khan MA, Joseph C, et al., Whole -exome sequencing analyses of inflammatory bowel Disease− Associated colorectal cancers,
    [18] Yaeger R, Shah MA, Miller VA, Kelsen JR, Wang K, Heins ZJ, et al., Genomic alterations observed in colitis-associated cancers are distinct from those found in sporadic colorectal cancers and vary by type of inflammatory bowel disease, Gastroenterology 2016;151:278-287. e276.
    [19] Romano M, De Francesco F, Zarantonello L, Ruffolo C, Ferraro GA, Zanus G, et al., From inflammation to cancer in inflammatory bowel disease: molecular perspectives, Anticancer research 2016;36:1447-1460.
    [20] Beksac K, Beksac M, Dalva K, Karaagaoglu E, Tirnaksiz MB, Impact of “killer immunoglobulin-like receptor/ligand” genotypes on outcome following surgery among patients with colorectal cancer: activating KIRs are associated with long-term disease free survival, PloS one 2015;10:e0132526.
    ACCEPTED MANUSCRIPT
    [21] Hernandez EG, Partida-Rodriguez O, Camorlinga-Ponce M, Nieves-Ramirez M, Ramos-Vega I, Torres J, et al., Genotype B of Killer Cell Immunoglobulin-Like Receptor is Related with Gastric Cancer Lesions, Scientific reports 2018;8:6104.